Nirma's purchase of 75% of Glenmark Life Sciences boosts its pharmaceutical industry standing. GLS offers unique APIs for chronic diseases globally. Glenmark Pharma's board sanctioned the sale of 7.84% stake in GLS through an offer for sale on the stock exchange. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
